secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2026-08-17T20:05:37+00:00
Accession:  0001213900-26-090747
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA to merge with Noble Africa, rename to Noble Africa Inc.; Q2 net income $160K
--------------------------------------------------------------------------------

- Merger with Noble Africa to rename ENDRA to Noble Africa Inc.; close expected Q4 2026.
- Private placement of ~$50M gross proceeds with institutional investors and ASP Isotopes, concurrent with merger close.
- Q2 2026 net income $160K vs net loss $1.2M in Q2 2025; cash $1.7M, restricted cash $3.8M, digital asset treasury $1.9M.
- Completed $3.8M private placement in May 2026; R&D expenses down 39%, sales & marketing down 92% YoY.
- Operating expenses $1.5M vs $1.3M; includes $542K non-cash stock comp vs $89K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000121390026090747/0001213900-26-090747-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000121390026090747/ea0302156-8k425_endra.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-090747

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer